SEOUL, South Korea , Oct. 23, 2024 /PRNewswire/ -- J INTS BIO , a leader in oncology drug development, has revealed interim preclinical results of its second-generation synthetic HSP90 inhibitor, JIN-001, at the ENA (EORTC-NCI-AACR) Symposium held in Barcelona, Spain , from October 23-25, 2024 . The findings demonstrate JIN-001's potential as a new therapeutic option for cancer patients who have developed drug resistance after treatment, representing a significant advancement in addressing this critical challenge.
JIN-001: A Novel Approach to Overcoming Chemotherapy Resistance in Ovarian Cancer Ovarian cancer remains one of the most aggressive and lethal gynecological malignancies, with approximately 70% of patients diagnosed at an advanced stage. While many patients initially respond to standard chemotherapy, drug resistance eventually develops, leading to disease progression and cancer relapse. JIN-001 was designed to address this issue and by targeting heat shock protein 90 (HSP90), a molecular chaperone that plays a crucial role in enabling cancer cells to adapt to therapeutic stress and survive.
By inhibiting HSP90, JIN-001 disrupts the ability of cancer cell to evolve and acquire resistance to the chemotherapy, thereby maintaining the effectiveness of existing standard treatment options. The preclinical studies presented at the symposium specifically explored the drug's efficacy when used in combination with established chemotherapeutic agents, offering new hope for pat.
